This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jasinski, D. R. Search for Related Content PubMed PubMed Citation Articles by Jasinski, D. R. Social Bookmarking                         What's this?

An evaluation of the abuse potential of modafinil using methylphenidate as a reference

Clinical Pharmacology/Chemical Dependence/Comprehensive Care Practice, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

Modafinil is a unique wake-promoting agent. Preclinical studies indicate a mechanism of action which is distinct from that of amphetamine or methylphenidate. To compare the pharmacodynamic profiles of modafinil, methylphenidate, and placebo in humans, a double-blind Latin square crossover study was conducted in 24 male volunteers with a history of polysubstance abuse that included the stimulant cocaine. Each subject was given single oral doses of methylphenidate (45 mg or 90 mg), modafinil (200 mg, 400 mg or 800 mg) and placebo. Measures of subjective, behavioural, and physiological responses were evaluated at fixed intervals during 72 h after each dosing occasion. Subjects discriminated both modafinil and methylphenidate from placebo. Subjects liked the effects of both drugs. However, modafinil differed from methylphenidate in its lack of a significant response on the Amphetamine Scale of the Addiction Research Center Inventory. The profile of physiological effects for modafinil differed from methylphenidate in that it showed greater inhibition of observed and reported sleep, less facilitation of orthostatic tachycardia and less reduction of caloric intake. These findings are consistent with preclinical pharmacological data suggesting that modafinil is not an amphetamine-like agent.

Journal of Psychopharmacology, Vol. 14, No. 1, 53-60 (2000)
DOI: 10.1177/026988110001400107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Zack and C. Poulos Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity J Psychopharmacol, August 1, 2009; 23(6): 660 - 671. [Abstract] [PDF]

				B. Ng and A. O'Brien Beyond ADHD and narcolepsy: psychostimulants in general psychiatry Adv. Psychiatr. Treat., July 1, 2009; 15(4): 297 - 305. [Abstract] [Full Text] [PDF]

				N Mann and P Bitsios Modafinil treatment of amphetamine abuse in adult ADHD J Psychopharmacol, June 1, 2009; 23(4): 468 - 471. [Abstract] [PDF]

				D. Jasinski and S Krishnan Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers J Psychopharmacol, June 1, 2009; 23(4): 410 - 418. [Abstract] [PDF]

				A Spathis, R Dhillan, D Booden, K Forbes, K Vrotsou, and K Fife Modafinil for the treatment of fatigue in lung cancer: a pilot study Palliative Medicine, June 1, 2009; 23(4): 325 - 331. [Abstract] [PDF]

				D. Jasinski and S Krishnan Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse J Psychopharmacol, June 1, 2009; 23(4): 419 - 427. [Abstract] [PDF]

				W.-M. Qu, Z.-L. Huang, X.-H. Xu, N. Matsumoto, and Y. Urade Dopaminergic D1 and D2 Receptors Are Essential for the Arousal Effect of Modafinil J. Neurosci., August 20, 2008; 28(34): 8462 - 8469. [Abstract] [Full Text] [PDF]

				D. A. Parasrampuria, K. A. Schoedel, R. Schuller, J. Gu, P. Ciccone, S. A. Silber, and E. M. Sellers Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans J. Clin. Pharmacol., December 1, 2007; 47(12): 1476 - 1488. [Abstract] [Full Text] [PDF]

				S. Morein-Zamir, D. C. Turner, and B. J. Sahakian A Review of the Effects of Modafinil on Cognition in Schizophrenia Schizophr Bull, November 1, 2007; 33(6): 1298 - 1306. [Abstract] [Full Text] [PDF]

				C. P. O'BRIEN, C. A. DACKIS, and K. KAMPMAN Does Modafinil Produce Euphoria? Am J Psychiatry, June 1, 2006; 163(6): 1109 - 1109. [Full Text] [PDF]

				T. J. Spencer, J. Biederman, P. E. Ciccone, B. K. Madras, D. D. Dougherty, A. A. Bonab, E. Livni, D. A. Parasrampuria, and A. J. Fischman PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate Am J Psychiatry, March 1, 2006; 163(3): 387 - 395. [Abstract] [Full Text] [PDF]

				F. J. Vocci, J. Acri, and A. Elkashef Medication Development for Addictive Disorders: The State of the Science Am J Psychiatry, August 1, 2005; 162(8): 1432 - 1440. [Abstract] [Full Text] [PDF]

				K R Kaufman and R Gerner Modafinil in sports: ethical considerations Br. J. Sports Med., April 1, 2005; 39(4): 241 - 244. [Abstract] [Full Text] [PDF]

				I. Taneja, A. Diedrich, B. K. Black, D. W. Byrne, S. Y. Paranjape, and D. Robertson Modafinil Elicits Sympathomedullary Activation Hypertension, April 1, 2005; 45(4): 612 - 618. [Abstract] [Full Text] [PDF]

				S. G. Sugden and J. A. Bourgeois Modafinil Monotherapy in Poststroke Depression Psychosomatics, February 1, 2004; 45(1): 80 - 81. [Full Text] [PDF]

				A. I. Pack Should a Pharmaceutical Be Approved for the Broad Indication of Excessive Sleepiness? Am. J. Respir. Crit. Care Med., January 15, 2003; 167(2): 109 - 111. [Full Text] [PDF]